Physician profile
John C House
NPI 1346348133
$1,105.23
in general payments reported to CMS, 2019-2025
24 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $110 · 2021: $206 · 2022: $138 · 2023: $122 · 2024: $184 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $218.19 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $205.10 | 2019-2025 | Veozah, Myrbetriq |
| Boston Scientific Corporation | $169.60 | 2021-2025 | Varithena Administration Pack, General - Pain Management |
| Abbvie INC. | $94.79 | 2021-2023 | |
| Vertos Medical, INC. | $56.50 | 2021 | |
| Genentech USA, INC. | $43.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.95 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.63 | 2019-2024 | Trulance, Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $28.02 | 2022 | |
| Vanda Pharmaceuticals INC. | $18.55 | 2025 | Fanapt |
| Organogenesis INC. | $18.35 | 2022 | |
| Scilex Pharmaceuticals INC. | $17.21 | 2021 | |
| Corcept Therapeutics | $15.75 | 2024 | Korlym |
| Pfizer INC. | $15.28 | 2023 | |
| Glaxosmithkline, LLC. | $15.00 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $14.63 | 2019 | |
| Abbott Laboratories | $14.44 | 2021 | |
| Amgen INC. | $14.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.10 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.88 | 2023 | |
| Aytu Biopharma, INC. | $13.55 | 2020 | |
| Nevro Corp. | $13.42 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.02 | 2020 | |
| Allergan, INC. | $12.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John House listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.